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ABSTRACT  
Introduction: Mesenchymal stem cells (MSCs) were described as adherent cells with a fibroblast-like appearance, have a great capacity for self-
renewal while maintaining their multipotency and differentiation into multiple tissues in vivo and in vitro. Methods: MSCs were isolated from 
cord blood of Sudanese donors using Ficoll-Hypaque gradient density protocol, and differentiate into β- like cells using 3-step protocol. STZ 
induced diabetic rats were injected intraperitoneally with the differentiated islet β- like cells and blood glucose levels were monitored for seven 
days. Results: The adherent cell appeared round and sphere after one-week of incubation, and the fibroblast-like colony was strongly attached 
after three weeks of seeding. The phenotyping of cells showed positivity for CD13, and negativity for CD34, CD45 and HLADR. MSCs were 
induced into islet-like cells using a 3-step (15-days) protocol. The differentiated cells showed positive diathizone stain and positive imuno-
reactivity to anti-human insulin antibody. Secretion of insulin by insulin-producing cells showed positive result with >3.4 u/ml scale reading in 
high glucose concentration medium. After one-week of transplantation the level of blood glucose was reduced from 410 to 225 mg/dl in the 
experimental rat. Conclusion: Human UCB-MSCs can be differentiated into insulin-secreting cells invitro, and are able to produce and secrete 
insulin in response to high glucose concentration in vivo and in vitro. 
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INTRODUCTION 
Mesenchymal stem cells (MSCs) have a potential to 
differentiate into diverse somatic lineages. They were 
adherent cells with a fibroblast-like appearance capable of 
differentiating into osteocytes, chondrocytes, adipocytes, 
tenocytes and myocytes [1]. During embryonic development 
MSCs are derived from the mesodermal germ layer, the 
mesoderm forms the connective tissue and the 
haematopoietic system [2]. Some scientists argue that MSCs 
and fibroblasts are functionally identical[3].The cultured 
MSCs express on their surface CD73,CD90 and CD105[4]. 
Stro-1, CD44, CD71 (transferring receptor), the ganglioside 
GD2 and CD271 (low-affinity nerve growth factor receptor). 
Cell adhesion molecules including intercellular adhesion 
molecule-1,-2 (ICAM-1,-2), integrins, activated leukocyte-cell 
adhesion molecule (ALCAM) and lymphocyte function-
associated antigen 3[5].Surface markerco-stimulatory 
molecules CD40, CD80, and CD86 [4]. MSCs can be isolated 
from different tissues such as fetal or adult tissue, adipose 
tissues, fetal liver, cord blood and mobilized peripheral 
blood, fetal lung, placenta, umbilical cord dental pulp, 
synovial membrane, periodontal ligament, endometrium, 
trabecular and compact bone[5]. 
The cells in the umbilical cord blood (UCB) are excellent 
source of MSCs. However, these cells are regarded as 
medical waste in the delivery roomsin many hospitals [MSCs 
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were isolated from the mononuclear cell [6] fraction of cord 
blood (CB) using various criteria including adherence to the 
surface of the culture medium. Negative expression of 
hematopoietic markers such as CD34, CD133, CD45, CD14 
and positive expression of mesenchymal markers such as 
CD90, CD105 CD73 [7]. The isolated UCB-MSCs were shown 
to differentiate into a wide range of cell types. However, 
there is no unique phenotype for MSCs derived from CB and 
from other sources. Therefore, the isolation and 
characterization of MSCs are rely on their ability to adhere to 
plastic and expand [8]. In the culture, the morphology of 
hUCB-MSCs demonstrates a typical MSCs 
immunophenothypic markers and fibroblastoid morphology. 
The absence of endothelial CD31 and leukocyte surface 
markers supports the involvement of UCB-MSCs as 
mesenchymal progenitors. In addition, hUCB-MSCs are 
devoid from hematopoietic and endothelial markers such as 
CD14, CD28, CD31, CD33, CD34, CD45, CD56 CD133, and 
HLA-DR. Therefore, hUCB-MSCs can be regarded as a novel 
source of human MSCs for clinical applications [9].  In the 
present study MSCs were isolated from cord blood and 
differentiated in vitro into insulin-producing cells. After that, 
the therapeutic effect of islet β-like cells wasdetermined in 
vivo using experimental rats. 
MATERIALS AND METHODS 
Cord blood samples 
This experimental study was conducted at the National 
Center for Neurological Sciences (NCNS) in Khartoum, 
Sudan. Cord blood samples were taken from healthy 
Sudanese women donors, at age less than 30 years subjected 
to full term spontaneous vaginal delivery.  5 to 10 ml of cord 
blood was collected from each donor in lithium heparin 
containers and processed  within one hour .Informed 
consent was obtained from parents two months before the 
date of delivery; all procedures and the objectives of study 
were clearly explained. 
Isolation of mononuclear cells 
In sterile falcon tube,5 ml of cord blood was added to 10ml 
Ficoll-Hypaque solution (1.077 g/mL; Sigma-Aldrich Co, St. 
Louis, Mo),two clear separate layers appeared. The mixture 
was centrifuged at 500g for 30minutes at room temperature, 
three layers were formed, mononuclear cells (MNCs) were 
carefully collected from the middle layer. The cells were 
suspended in 10ml of Dulbecco modified Eagle medium 
(Biowest co) and centrifuged at 400 rpm for 7minutes. The 
supernatant was discarded and the pellet containing MNCs, 
was suspended in10 ml of low glucose Dulbecco modified 
Eagle medium (L-DMEM) supplemented with 10% fetal 
bovine serum (Invitrogen) and 1% of penicillin 
/streptomycin (Biowest co), then cells were transferred into 
tissue culture bottle and incubated in 5% Co2 at 37o C. 
Counting viable cells  
According UCL-EH&S protocol, in sterile eppendorf tube 90 
µl of trypan blue was added to 10µl of cells suspension, and 
gently vortexed. Adequate volume of the mixture was placed 
in haemocytometer (MARIENFELD), incubated at room 
temperature for two minutes, then counted using inverted 
microscope (Motic-AE20). 
Mesenchymal Stem Cells Culture 
Three ml of L-DMEM (supplemented with 10% fetal bovine 
serum,1% of (100u) penicillin/streptomycin) was added to 
500µl of mononuclear cells in sterile tube and centrifuged at 
1500 rpm for 5 minutes. The supernatant was discarded; 
3ml of the media was added to the pellet and mixed. The 
mixture was transferred into 60cm petri-dish (Nest 
Biotechnology.com) (according to the seeding density of the 
petri dish) and incubated at 37oC in Co2 incubator (humidity 
96%) for 24hrs. The culture medium was changed every 
three days, and cells were passage when the confluence 
reached 80-90%.  
Flow cytometry 
To detect the cell surface antigen phenotype, the cells were 
detached after passage3 and stained with flurochrome 
coupled with CD13, CD34, CD45 and HLADR antibodies and 
analyzed with FACSCalibur (Becton Dickinson).  
Invitro differentiation of Mesenchymal Stem Cells 
Cells from passage 3 were induced to differentiate into 
insulin-secreting cells by a 3-step protocol. In step 1 the cells 
were incubated for 24 hrs in high glucose Dulbecco modified 
Eagle medium (H-DMEM; 25 mmol/L glucose) 
supplemented with 10% fetal bovine serumand1µ M of 
retinoic acid (sigma).Then incubated for another 2 days in 
H-DMEM (biowest co) with 10% fetal bovine serum. In 
step2; the cells were seeded in extracellular matrix (ECM) 
gel coated well plates(Gibco) in low glucose Dulbecco 
modified Eagle medium(L-DMEM), supplemented with 10% 
fetal bovine serum, 10 mmol/L nicotinamide (stem cell 
technologies) and 20-ng/mL epidermal growth factor 
(Thermofisher scientific) for 6 days. In step 3, to induce 
maturation insulin-producing cells was incubated in low 
glucose medium (supplemented with 10% fetal bovine 
serum and 10nmol/L exendin- 4(TOCRIS)) for 6 days.  
Dithizone staining  
The differentiated cells were incubated in 10 µl of dithizone 
staining solution at 37ºC for 20 minutes then examined 
under inverted microscope. 
Immunocytochemical staining for insulin 
To detect insulin production, cells were stained using 
Dakocytomation En Vision+ Dual system –HRP Kit 
(Dakocytomation) and mouse anti-human insulin antibody 
(ZYTOMED systems) according to the manufacture protocol. 
Measurement of spontaneous insulin secretion   
After 15 days of differentiation, the cells were incubated in 
DMEM at different concentrations of glucose (5.5 mmol/L, 
28mmol/L).  Insulin concentration in the media was 
determined using insulin ELIZA kit (IMMUNOSPEC 
CORPORATION) according to the manufacture protocol. 
Animal experiment 
Four Albino Wistar rats, aged (6 to 15 weeks) old, weighed 
(165-205g) were obtained from the Experimental Animals 
Center, Faculty of Veterinary Medicine, University of 
Khartoum, Sudan. To induce type 1 DM, 30mg/kg of 
sterptozotocin (STZ) solution in acidified saline (pH4.5) was 
injected intraperitonelly into the rats on 3 consecutive days. 
Rats were divided into control group and transplantation 
group, 2 rats for each. Three days after STZ injection, the rats 
in the transplantation group were injected intraperitonelly 
with 6x106 differentiated insulin producing cells suspended 
in 1ml of normal saline. Blood samples were collected from 
the tail vein every day, and glucose level in the blood was 
measured using blood glucose meter (ONE TOUCH, 
select).The experimental protocol was conducted following 
the guide for the care and use of laboratory animals 
prepared by the Faculty of Veterinary Medicine, University 
of Khartoum.  
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RESULTS  
Isolation of human mesenchymal stem cells from cord 
blood 
All blood samples were screened for HIV, HBV, and HCV. In 
day one of incubation, significant number of RBCs and WBCs 
were seen under inverted microscope (Fig. 1), while in day 6 
of incubation the RBCs and WBCs were completely absent. 
The number of cells per passage from cord blood samples 
ranged (136.5x104- 218.8x104) in passage 1, (272 x104- 
560.6 x104) in passage 2 and (487.5 x104-1012.5 x 104) in 
passage 3. The typical shape of MSCs was identified 3 weeks 
after incubation (Fig. 2). 
 
 
Figure 1.Day one incubation, shows the abundant number of RBCS and WBCS from cord blood samples   (X40) 
 
A B 
C D 
Figure 2. Microscopic photos of MSC isolation stage, A passage one shows clusters of MSC, B passage 2 shows separated cells,C 
and D passage 3 shows an increasing number of MSC. Magnification:  A,B and D X40, C X10. 
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Phenotypic characterization of mesenchymal stem cell by flow cytometry 
Phenotypic characterization of cord blood showed positive CD13 (Fig. 3), and negative CD34, CD 45 and HLA-DR markers(Fig. 
4). 
 
Figure 3. Flow cytometry phenotypic characterization of MSCs from the cord blood, positive for CD13 
 
 
Figure 4.Flow cytometry phenotypic characterization of MSCs from cord blood, negative for CD 34, CD45 and HLA-DR. 
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In vitro differentiation of mesenchymal stem cell from cord blood into insulin –producing cell 
In Step 1, no changes were detected in mesenchymal stem cell morphology.  In Step 2 the proliferation rate was decreased and 
the MSCs shape become short and round.  In Step 3 clusters of islet -like cell were formed (Fig. 5). 
A B 
Figure5. CB-MSCs differentiated to β-like cells. A shows differentiated cells in Step2 differentiated protocol, B shows 
differentiated cell in Step3 differentiated protocol. Magnification x40. 
 
Detection of insulin inside the differentiated cell by diathizone stain  
Diathizone staining showed the β-like cells in red color indicating positivity insulin production (Fig.6). 
 
Figure 6.Diathizone stain for insulin producing cells from CB-MCS, the red color is an indicator for positive insulin production. 
Magnification; 40X. 
Immune cytochemical staining for insulin 
Positive imuno-reactivity to anti-human insulin antibody was detected in all differentiated β-like cells (Fig.7). 
A B 
Figure 7.Imuno-reactivity to anti-human insulin antibody A and B, CB-MCS. The brown color is an indicator for positive insulin 
production. Magnification; A and B X40. 
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Measurement of insulin secretion by insulin- producing 
cells     
Concerning insulin concentration; ELISA analysis showed 
negative results in low glucose  medium with 0.00 scale 
reading, while high glucose medium showed positive results 
with >3.4 u/ml scale reading (Table 1). 
 
Table 1.Glucose challenge test 
Sample Low glucose concentration High glucose concentration 
Absorbance Interpretation u/ml Absorbance Interpretation u/ml 
Sample 1 CB-MSC 0.295 0.0 0.362 3.9 
Sample 2 CB-MSC 0.268 0.0 0.325 3.5 
Sample 2 CB-MSC 0.286 0.0 0.319 3.4 
 
Animal experiment 
The rats began to show hyperglycemia after 72 hours of STZ 
injection and after one-week of transplantation, blood 
glucose levels were reduced from 420 mg/dl and 400 mg/dl 
to 200 mg/dl and 250 mg/dl respectively while the STZ 
control group showed hyperglycemia with more than 500 
mg/dl. 
DISCUSSION 
Mesenchymal stem cells have been isolated from bone 
marrow and other tissues [10] . To date, BM-MSC are the best 
described, they serve as a standard to which other sources of 
MSC are compared. The present study adopted technique 
commonly used in the literature for MSC isolation from cord 
blood; Ficoll-Hypaque gradient density protocol [11] and low 
glucose Dulbecco modified Eagle medium (L-DMEM) 
supplemented with 10% of fetal bovine serum [12]. The 
adherent cell appeared round and sphere in shape after one-
week incubation and the fibroblast like colony was seen 
attached three weeks after the first seeding. Detachment of 
the colony was done using trypsin enzyme. While Zeddou et 
al described that the adherent cells appeared like 
macrophage with limited proliferation capacity and not 
detached upon trypsin treatment [13].  
 Based on the ISCT guide lines; CD105, CD73,CD90,CD44, 
CD13 were positive markers for MSC in general, while CD34, 
CD45 and HLADR were negative markers [14]. In this study 
CD13 was positive in cord blood, while CD34, CD45 and 
HLADR were negative. Several studies suggested cord blood 
as a source of MSCs, while MSCs from cord blood were 
present at low frequencies [13]. The previous study indicated 
that the rate of MSC was 29% from processed cord blood 
units, and it could be enhanced to 63% by coating the 
culture flask with FBS [15]. In the present study MSCs were 
isolated from all units of cord blood. In addition, the growth 
rate in non-coated flask was very high, but these results are 
not confirmed due to sample size limitation when compared 
with other studies (this was the first study in Sudan).  
Heavy adherent fibroblastoid cells were obtained from full-
term UCB, despite the finding of many studies that the 
preterm UCB contains more adherent fibroblastoid cells 
than full-term UCB [16], In vitro differentiation of MSCs into 
insulin producing cells is well documented, using multistep 
differentiation protocols. MSC derived insulin-producing 
cells can be obtained from a variety of human tissues; bone 
marrow, adipose tissue, umbilical cord or its blood and 
endometrium [17]. In this study islet-like clusters were 
obtained from human UCB-MSCs using a 3-step protocol. 
These induced cells expressed pancreatic cell markers, 
synthesized and secreted functional islet protein (insulin). 
The induced cells were cultured in high-glucose media 
supplemented with retonic acid. The combination of high 
glucose and retonic acid specifically activates pancreatic 
endocrine cell differentiation from UCB-MSCs [18].  
Maturation factors such as nicotinamide, epidermal growth 
factor (EGF) and exendin-4 were used in culture. 
Morphologic changes of cells were observed after addition of 
nicotinamide and EGF in step2. Nicotinamide induces islets 
formation from pancreatic progenitor cells, trans 
differentiation and maturation into insulin-producing cells 
and EGF increases the number of undifferentiated cells [19] 
.In step 3; Exendin-4 was added in the induction system, the 
cells matured quickly with more formation of islet-like 
clusters and the functional islet’s protein was detected. Gao 
et al demonstrated that, the microenvironments are 
important in differentiation of stem cells. ECM has been 
shown to play a crucial role in cell differentiation through 
rearrangement of the cytoskeletal network, essential for 
pancreatic progenitor cell migration, the 3-dimensional 
cystic structures formation and protrusion of the islet bud 
[20]. Another study obtained insulin-secreting cells from 
mouse MSCs without ECM gel coated, the induction 
strategies took about 2-4 months and no cluster were 
formed [20]. In this study, Petri dishes coated with ECM gel 
were used and clusters were formed with functional islet’s 
protein secretion in 15 days. 
The insulin content of insulin-secreting cells was low, and 
glucose induced-insulin secretion and its proportion were 
lower than those in native islets [11], while in our study 
insulin was expressed in most cells. Fenget al. proved that 
UCB-MSCs were capable of differentiating into insulin-
secreting cells invitro by the 3-step protocol. However, these 
cells were immature regarding insulin production and 
glucose responsiveness [11]. Parekhet al. used 270 cord blood 
samples to evaluate the ability of cord blood mononuclear 
cells to differentiate into islets and found that MSCs were 
inefficient to dedifferentiate into beta cell because they are 
mesodermal in origin where beta cells are endodermal. 
Although the phenotypic change of MSCs into islets was 
reported, the functional ability of the differentiated islet-like 
structures was not demonstrated [22] While in this study 
human UCB-MSCs were capable of differentiating into 
insulin-secreting cells in-vitro by the 3-step protocol and 
these cells were able to produce and secrete insulin in 
response to high glucose concentration.  
In the present study, two groups of rats were used to 
evaluate the possibility of using IPC for therapy. In STZ 
treated group that received the differentiated cells (IPC), the 
blood glucose levels were reduced from 420 and 400 to 
become 200 and 250 mg/dl one week after transplantation 
while on Tsai et al. study, blood glucose levels decreased on 
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the fourth week after transplantation to approximately 
250mg/dl in the DM rats compared to 530 mg/dl in the STZ 
control rats. They believed that transplantation may slow 
down the appearance of symptoms of DM rather than curing 
the disease [23].  
CONCLUSION 
Human UCB-MSCs are capable of differentiating into insulin-
secreting cells in vitro by the 3-step protocol and able to 
produce and secrete insulin in vitro and in vivo in response 
to high glucose concentration.  
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